NMN Pharmacokinetics, Metabolism, and Bioavailability

Why this page uses precise terminology

These terms get blurred constantly in NMN marketing, so this page uses them precisely. Absorption is whether and how much of an orally administered substance crosses the gut wall into the body. Bioavailability is the fraction of an administered dose that reaches systemic circulation unchanged — technically only measurable by comparing oral dosing against an intravenous reference dose of the same compound, which no published human NMN study has done. Pharmacokinetics (PK) is the full time-course of a compound in the body: how fast it appears (absorption), where it goes (distribution), how it's broken down (metabolism), and how it's cleared (excretion) — usually summarized as Tmax (time to peak concentration), Cmax (peak concentration), AUC (total exposure over time), and half-life. None of these is the same as "blood NAD+ went up after taking NMN," which is a downstream biomarker change, not a measurement of NMN itself moving through the body.

What has actually been measured in humans

The most directly relevant human study measured plasma metabolites after single oral doses of NMN (100, 250, and 500 mg) in healthy Japanese men.[1] Critically, this study did not measure intact NMN in plasma — it measured two downstream methylated nicotinamide metabolites, N-methyl-2-pyridone-5-carboxamide (2PY) and N-methyl-4-pyridone-5-carboxamide (4PY), which rose in a dose-dependent manner over a 5-hour observation window.[1] This confirms that something derived from the administered NMN entered systemic circulation and was metabolized in a dose-dependent way. It does not establish Tmax, Cmax, AUC, or half-life for NMN itself, because NMN itself was not the analyte measured.

Other human trials add blood NAD+ trajectories over days to weeks of repeated dosing — a biomarker endpoint, not a single-dose PK curve. NAD+ has been shown to rise in a dose-dependent way across a published dose-response trial[2], and no changes exceeding normal physiological variation were observed on safety-panel measures in a high-dose safety study.[3] These are useful for establishing that repeated oral NMN reliably raises blood NAD+ (covered in full on NMN Human Clinical Trials), but they are not pharmacokinetic parameters.

What has not been established in humans

Absolute oral bioavailability of NMN has not been established in humans. No published study has administered NMN both orally and intravenously to the same population and compared systemic exposure, which is the only way to calculate a true absolute bioavailability figure. Likewise, no published human study reports a formal Tmax, Cmax, AUC, or elimination half-life for intact NMN in plasma; urinary excretion of intact NMN has not been quantified in humans; and human tissue distribution of NMN or its metabolites has not been directly measured — tissue-distribution data exist only in animal studies, which involve different physiology, dosing routes, and timescales and cannot be assumed to transfer directly to humans (see Preclinical vs. Human NMN Evidence).

Metabolism: what's established biochemistry vs. what's been directly measured

The biochemical pathway from NMN to NAD+ — via NMNAT-catalyzed adenylylation, covered in full on NMNAT Enzymes Explained — is established biochemistry, studied extensively in cell and animal systems. What is genuinely uncertain is the human-specific route by which extracellular, orally-administered NMN reaches the inside of human cells before that pathway can act on it. As covered in depth on NMN Transport and Cellular Uptake, the mechanism proposed for direct NMN uptake (the transporter SLC12A8) was disputed shortly after publication, and the alternative route — extracellular NMN dephosphorylated to nicotinamide riboside (NR) before cellular entry — remains the more widely supported model for humans. A downstream rise in blood or intracellular NAD+ after oral NMN does not, by itself, prove that NMN entered cells intact; it is consistent with several different upstream routes, and this page does not assume direct intact-cell uptake simply because NAD+ rises.

What this means in practice

The honest summary: oral NMN administration produces a measurable, dose-dependent downstream metabolic signature in humans (methylated nicotinamide metabolites, and over longer dosing, blood NAD+ itself), demonstrating that something happens after ingestion. But classical pharmacokinetic characterization of NMN in humans — the parameters that would let a clinician or researcher precisely describe its absorption, distribution, metabolism, and excretion — remains incomplete. Readers should treat any specific bioavailability percentage, Tmax, or half-life figure for NMN quoted elsewhere as unsupported by the currently published human literature unless a specific primary study is cited.

Related reading

For the safety implications of these unknowns, see NMN Safety and Side Effects. For how NMN is absorbed and metabolized generally, see How NMN Is Absorbed and Metabolized. For dosing actually used in trials, see NMN Dosage. For the complete trial record, see NMN Human Clinical Trials.